Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Апрель 10, 2025

Anti-double-stranded DNA (anti-dsDNA) antibodies at abnormal titer are of considerable diagnostic value for systemic lupus erythematosus (SLE). Current assays detecting anti-dsDNA show divergent properties, emphasizing the importance selecting suitable assays. This study aims to investigate performance indirect immunofluorescence (IIF), digital liquid chip method (DLCM), chemiluminescence immunoassay (CLIA), and their combinations in SLE. We conducted a retrospective, single-center from 2022 2023 which included 3429 samples: 1773 patients with SLE 1656 controls rheumatoid arthritis (RA) Sjögren's syndrome (SS). Sensitivity, specificity, accuracy, positive predictive (PPV), negative (NPV) detection by IIF, DLCM, CLIA were calculated. Cohen's kappa coefficient was used evaluate inter-method agreement. The correlations between concentration SLEDAI-2k scores/renal involvement assessed. Among individual assays, IIF demonstrated highest specificity (98.31%) PPV (96.10%) but lower sensitivity (38.92%) compared (41.57%) DLCM (43.65%) (p < 0.05). Combining two significantly improved while maintaining specificity>95%. combination achieved 52.2% an AUC 0.76. Substantial agreement observed (κ = 0.78), whereas other moderate 0.65-0.66). In longitudinal analysis 88 patients, detected antibody fluctuations more reliably than IIF. Anti-dsDNA levels or positively correlated SLEDAI-2K scores (R=0.42 0.29, p<0.05). Both methods showed significant differences without renal provided higher single (p<0.001) subgroups. Our findings demonstrate that performs comparably CLIA, supporting its clinical potential. Moreover, combining enhances sensitivity, particularly subgroups involvement.

Язык: Английский